News Introduction

Tianeptine sodium(CAS 30123-17-2) belongs to novel tricyclic antidepressants

Date : 2016/8/22 11:51:04

Tianeptine sodium(CAS 30123-17-2) is antidepressant drugs: depression as a common mental disorders, its incidence has increased year after year. World Health Organization 2005 statistics, the prevalence of a variety of depression about 11% of the global population. Domestic information reports, China has at least 36 million patients with depression, of which only 5% of patients with severe treatment related, 62% of patients with depression never seek medical treatment after state. Of suicide and attempted suicide in depressed patients population accounted for 50% to 70%. World Health Organization predicts that by 2020, in addition to cardiovascular disease, depression will be the impact of life and increase the financial burden of the second largest disease, a major killer of the 21st century human health. However, depression on physical and mental health, family and serious harm to society, has yet to arouse people (including patients and non-specialist clinicians) enough attention, patients neglect treatment, diagnosis and treatment of doctors misdiagnosis rate is relatively high , which should pay close attention. Accordingly, it is the disease clinically relevant drug studies were reviewed.

Novel tricyclic antidepressants:

Tianeptine sodium(CAS 30123-17-2) is one of the on behalf drug. Listed 1980s novel tricyclic antidepressants, it SSR is reuptake opposite effects, mainly by increasing presynaptic reuptake 52HT play a role. This class of new drugs to maintain the efficacy of tricyclic antidepressants, fluoxetine efficacy and safety equal. For single-phase, two-phase recurrent and severe depression have a better effect, and depression after chronic alcoholism and alcohol are also effective. Especially for use in elderly patients with coexisting anxiety, somatic symptoms, and has anxiolytic effects without causing sedation. Less side effects, visible dizziness, dry mouth, gastrointestinal discomfort.